ArticleFrontiers in immunology2026
Integrated profiling of RUNX3 in intratumoral NK cells activity through bulk and single-cell transcriptomic analysis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Natural killer (NK) cells are core components of innate antitumor immunity, the dysfunction of NK cells in the tumor microenvironment is a major obstacle to the antitumor efficacy. Runt-related transcription factor 3 (RUNX3) acts as a critical tumor suppressor and regulates immune cell function, while its biological role in NK cells remains largely unexplored. Herein, we investigated the interaction between RUNX3 and NK cells in tumor microenvironment. Methods: The Cancer Genome Atlas (TCGA) database was utilized to determine the genetic alteration of RUNX3 in pan-cancer. TIMER and GEPIA website were used to evaluate the correlation between RUNX3 and immune cell infiltration. Single-cell RNA sequencing (scRNA-seq) analysis was applied to characterize RUNX3 expression and pseudotime trajectory in NK cells. Results: RUNX3 was significantly downregulated in lung adenocarcinoma and hepatocellular carcinoma tissues. Clinical analyses have demonstrated that defective RUNX3 expression was correlated with adverse prognosis. Immune infiltration analyses revealed that RUNX3 was positively associated with immune cell infiltration, particularly NK cells and CD8 Conclusion: Our findings identify RUNX3 as a key regulator of NK cell-mediated antitumor immunity in LUAD and LIHC, providing a novel molecular target for enhancing innate immune surveillance and developing targeted immunotherapies for the aggressive malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.